CGEM Cullinan Oncology Inc
Price (delayed)
$17.32
Market cap
$1B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.06
Enterprise value
$891.87M
Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build
Highlights
Cullinan Oncology's equity has soared by 54% from the previous quarter and by 31% YoY
CGEM's quick ratio is up by 43% from the previous quarter and by 13% YoY
CGEM's net income is down by 7% from the previous quarter
Key stats
What are the main financial stats of CGEM
Market
Valuations
Earnings
Shares outstanding
57.98M
Market cap
$1B
Enterprise value
$891.87M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.52
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$156.28M
EBITDA
-$155.97M
Free cash flow
-$126.81M
Per share
Balance sheet
Liquidity
EPS
-$3.06
Free cash flow per share
-$2.3
Book value per share
$11.39
Revenue per share
$0
TBVPS
$12.37
Total assets
$681.22M
Total liabilities
$25M
Debt
$2.73M
Equity
$656.22M
Working capital
$654.32M
Debt to equity
0
Current ratio
28.87
Quick ratio
28.22
Net debt/EBITDA
0.72
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27%
Return on equity
-28.4%
Return on invested capital
-37.4%
Return on capital employed
-23.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CGEM stock price
How has the Cullinan Oncology stock price performed over time
Intraday
-3.51%
1 week
-5.1%
1 month
3.65%
1 year
73.9%
YTD
69.97%
QTD
-0.69%
Financial performance
How have Cullinan Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$183.74M
Net income
-$142.16M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 13% YoY and by 7% from the previous quarter
CGEM's net income is down by 7% from the previous quarter
Growth
What is Cullinan Oncology's growth rate over time
Valuation
What is Cullinan Oncology stock price valuation
P/E
N/A
P/B
1.52
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 10% year-on-year and by 2.2% since the previous quarter
Cullinan Oncology's equity has soared by 54% from the previous quarter and by 31% YoY
The price to book (P/B) is 22% higher than the last 4 quarters average of 1.3
Efficiency
How efficient is Cullinan Oncology business performance
CGEM's return on invested capital is up by 6% year-on-year and by 4.6% since the previous quarter
Cullinan Oncology's return on equity has decreased by 6% YoY
The company's return on assets fell by 5% YoY
Dividends
What is CGEM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CGEM.
Financial health
How did Cullinan Oncology financials performed over time
CGEM's total assets has surged by 52% since the previous quarter and by 31% year-on-year
CGEM's quick ratio is up by 43% from the previous quarter and by 13% YoY
The debt is 100% smaller than the equity
CGEM's debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
Cullinan Oncology's equity has soared by 54% from the previous quarter and by 31% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.